Particularly, TNBC accounts for 5–25% of all breast cancers and is a clinical estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 negative tumors. This evidence concerns the gene ESR1 and breast carcinoma.